Chemioterapia con o senza immunoterapia per il mesotelioma peritoneale
Studio randomizzato di fase 2 sulla chemioterapia neoadiuvante o palliativa con o senza immunoterapia per il mesotelioma peritoneale
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior best response rate than carboplatin, pemetrexed and bevacizumab in patients with peritoneal mesothelioma as determined by Response Evaluation Criteria in Solid Tumors (RECIST).
SECONDARY OBJECTIVES:
I. To determine the safety, major pathologic response rates, and completeness of cytoreduction of patients treated with neoadjuvant carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab.
II. To determine the safety of patients treated with palliative carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab.
III. To determine whether frontline treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab results in a superior metabolic response rate than carboplatin, pemetrexed and bevacizumab as determined by Positron Emission Tomography (PET) Response Criteria in Solid Tumors.
IV. Explore the value that analysis of secondary computed tomography (CT) findings and quantitative fludeoxyglucose F-18 (FDG)-PET imaging adds to prognostic information and response assessment in this disease.
V. Determine the number of patients who were deemed to have unresectable disease who are able to undergo surgery following treatment with carboplatin, pemetrexed, bevacizumab and atezolizumab or carboplatin, pemetrexed and bevacizumab due to dramatic response.
VI. To compare the progression-free survival and overall survival between arms. VII. Results of the primary analysis will be examined for consistency, while taking into account the stratification factors and/or covariates of baseline quality of life (QOL) and fatigue.
EXPLORATORY OBJECTIVE:
I. To determine whether blood-based biomarkers including our recently described cell-free chromosomal junctions, soluble mesothelin-related peptides and megakaryocyte potentiating factor correlate with clinical outcomes data (i.e. overall survival [OS], progression-free survival [PFS], recurrence, response, etc.).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive atezolizumab intravenously (IV) over 30-60 minutes, bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive atezolizumab IV over 30-60 minutes and bevacizumab IV on day 1 of each maintenance therapy cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive bevacizumab IV with or without atezolizumab IV over 30-60 minutes on day 1 of each maintenance therapy cycle at the discretion of the investigator. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study.
After completion of study treatment, patients are followed up every 6 months for up to 3 years.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85054
- Sospeso
- Mayo Clinic Hospital in Arizona
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-702-8222
- Email: cancerclinicaltrials@bsd.uchicago.edu
-
Investigatore principale:
- Hedy L. Kindler
-
Chicago, Illinois, Stati Uniti, 60606
- Reclutamento
- Alliance for Clinical Trials in Oncology
-
Investigatore principale:
- Aaron S. Mansfield
-
Contatto:
- Aaron S. Mansfield
- Numero di telefono: 507-293-0569
- Email: mansfield.aaron@mayo.edu
-
Danville, Illinois, Stati Uniti, 61832
- Reclutamento
- Carle at The Riverfront
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@Carle.com
-
Effingham, Illinois, Stati Uniti, 62401
- Reclutamento
- Carle Physician Group-Effingham
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Mattoon, Illinois, Stati Uniti, 61938
- Reclutamento
- Carle Physician Group-Mattoon/Charleston
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Urbana, Illinois, Stati Uniti, 61801
- Reclutamento
- Carle Cancer Center
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Urbana, Illinois, Stati Uniti, 61801
- Reclutamento
- The Carle Foundation Hospital
-
Investigatore principale:
- Suparna Mantha
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Attivo, non reclutante
- University of Kentucky/Markey Cancer Center
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- Reclutamento
- Sanford Joe Lueken Cancer Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-333-5000
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Reclutamento
- Mercy Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Edina, Minnesota, Stati Uniti, 55435
- Reclutamento
- Fairview Southdale Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Edina, Minnesota, Stati Uniti, 55435
- Reclutamento
- Minnesota Oncology - Edina
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Fridley, Minnesota, Stati Uniti, 55432
- Attivo, non reclutante
- Unity Hospital
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Reclutamento
- Abbott-Northwestern Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic in Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 855-776-0015
-
Investigatore principale:
- Aaron S. Mansfield
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Reclutamento
- Park Nicollet Clinic - Saint Louis Park
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Reclutamento
- Regions Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Saint Paul, Minnesota, Stati Uniti, 55102
- Reclutamento
- United Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Willmar, Minnesota, Stati Uniti, 56201
- Reclutamento
- Rice Memorial Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Worthington, Minnesota, Stati Uniti, 56187
- Reclutamento
- Sanford Cancer Center Worthington
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Reclutamento
- Sanford Bismarck Medical Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Broadway Medical Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Roger Maris Cancer Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-234-6161
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- Ohio State University Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-293-5066
- Email: Jamesline@osumc.edu
-
Investigatore principale:
- John L. Hays
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Hassan Hatoum
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- UPMC Hillman Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 412-647-8073
-
Investigatore principale:
- Liza C. Villaruz
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Reclutamento
- Sanford Cancer Center Oncology Clinic
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Reclutamento
- Sanford USD Medical Center - Sioux Falls
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Texas
-
Conroe, Texas, Stati Uniti, 77384
- Reclutamento
- UT MD Anderson - The Woodlands
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Kanwal P. Raghav
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- UT MD Anderson Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 866-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Kanwal P. Raghav
-
Houston, Texas, Stati Uniti, 77079
- Reclutamento
- UT MD Anderson - West Houston
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Kanwal P. Raghav
-
League City, Texas, Stati Uniti, 77573
- Reclutamento
- UT MD Anderson - League City
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Kanwal P. Raghav
-
Sugar Land, Texas, Stati Uniti, 77478
- Reclutamento
- UT MD Anderson - Sugar Land
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-632-6789
- Email: askmdanderson@mdanderson.org
-
Investigatore principale:
- Kanwal P. Raghav
-
-
Wisconsin
-
Appleton, Wisconsin, Stati Uniti, 54911
- Reclutamento
- ThedaCare Regional Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-364-3604
- Email: ResearchDept@thedacare.org
-
Investigatore principale:
- Matthias Weiss
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Reclutamento
- Marshfield Medical Center-EC Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Michael Husak
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Reclutamento
- Marshfield Medical Center-Marshfield
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Michael Husak
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Reclutamento
- Marshfield Medical Center - Minocqua
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Michael Husak
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Reclutamento
- Marshfield Medical Center-Rice Lake
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Michael Husak
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Reclutamento
- Marshfield Medical Center-River Region at Stevens Point
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Michael Husak
-
Weston, Wisconsin, Stati Uniti, 54476
- Reclutamento
- Marshfield Medical Center - Weston
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Michael Husak
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Physicians should consider whether any of the following may render the patient inappropriate for this protocol:
-
Psychiatric illness which would prevent the patient from giving informed consent
-
Medical conditions such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with a "currently active" second malignancy other than non-melanoma skin cancers or cervical carcinoma in situ. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for >= 3 years
-
-
In addition:
-
Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)
- A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
-
-
Histologically or cytologically confirmed malignant peritoneal mesothelioma for which there has been no prior treatment. Given the indolent nature of well-differentiated papillary mesothelioma and multicystic mesothelioma, patients with these variants are not eligible for participation
-
Must have measurable disease per RECIST version (v) 1.1
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 28 days prior to registration is required
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
Leukocytes >= 2,500/mm^3
-
Absolute neutrophil count (ANC) >= 1,500/mm^3
-
Platelet count >= 100,000/mm^3
-
Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
Total bilirubin =< 1.5 x upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 3.0 x upper limit of normal (ULN)
-
Urine protein/creatinine (UPC) ratio < 1, or urine protein: =< 1+
-
No prior systemic therapy for peritoneal mesothelioma is allowed. No concurrent radiotherapy is allowed
-
No active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis, with the following exceptions:
- Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
- Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
-
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
- Rash must cover < 10% of body surface area
- Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
-
No history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
-
No prior allogeneic stem cell or solid organ transplantation
-
Central nervous system (CNS) metastases must have been treated with local therapy (surgery, radiation, ablation) with systemic steroids tapered to a physiologic dose (10 mg or prednisone equivalent or less)
-
Patients who have received live attenuated vaccines within 30 days of the first dose of trial treatment are eligible at the discretion of the investigator. All seasonal influenza vaccines and vaccines intended to prevent SARS-CoV-2 and coronavirus disease 2019 (COVID-19) are allowed
-
No history of inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)
-
No history of hypertensive crisis or hypertensive encephalopathy
-
No clinically significant cardiovascular disease, such as cerebrovascular accidents within 12 months prior to randomization, myocardial infarction within 12 months prior to randomization, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with study treatment
-
No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to randomization
-
No history of grade >= 4 venous thromboembolism
-
No history or evidence upon physical or neurological examination of central nervous system disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy
-
No history of grade >= 2 hemoptysis (defined as >= 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
No history or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)
-
No major surgical procedure or significant traumatic injury within 28 days prior to initiation of study treatment (diagnostic laparoscopy is allowed as part of diagnosing peritoneal mesothelioma)
-
No core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to initiation of study treatment
-
Placement of a vascular access device should be at least 2 days prior to initiation of study treatment
-
No active infection requiring IV antibiotics at the time of initiation of study treatment
-
No history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization
-
No serious, non-healing wound, active ulcer, or untreated bone fracture
-
No other malignancy within 5 years prior to randomization, except for localized cancer in situ, such as basal or squamous cell skin cancer
-
Patients with a creatinine clearance between 45 and 79 mL/min should not use ibuprofen or other nonsteroidal anti-inflammatory drug (NSAIDs) for 2 days before, the day of, and 2 days following pemetrexed administration
-
No treatment with immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:
- Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) may be eligible for the study
- Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm I (carboplatin, pemetrexed, bevacizumab, atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes, bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive atezolizumab IV over 30-60 minutes and bevacizumab IV on day 1 of each maintenance therapy cycle. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT scan
Altri nomi:
Undergo PET scan
Altri nomi:
Given IV
Altri nomi:
Undergo blood and tissue sample collection
Altri nomi:
Undergo surgery
Altri nomi:
Undergo HIPEC
Altri nomi:
|
|
Comparatore attivo: Arm II (carboplatin, pemetrexed, bevacizumab)
Patients receive bevacizumab IV, carboplatin IV, and pemetrexed IV on day 1 of each cycle. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 4-8 weeks, patients then undergo cytoreductive surgery and HIPEC. Patients not eligible for surgery OR patients for whom surgery was aborted, insufficient or lacking cytoreductive intent may receive bevacizumab IV with or without atezolizumab IV over 30-60 minutes on day 1 of each maintenance therapy cycle at the discretion of the investigator. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan, PET scan, and collection of blood and tissue samples throughout the study. |
Given IV
Altri nomi:
Given IV
Altri nomi:
Given IV
Altri nomi:
Undergo CT scan
Altri nomi:
Undergo PET scan
Altri nomi:
Undergo blood and tissue sample collection
Altri nomi:
Undergo surgery
Altri nomi:
Undergo HIPEC
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Response rate
Lasso di tempo: Up to 4 years after study activation
|
Will be compared between arms. |
Up to 4 years after study activation
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Major pathologic response rate
Lasso di tempo: Up to 3 years
|
The proportion of patients with a pathologic response will be calculated and compared between arms and 95% confidence intervals reported. The chi-square test will be used to compare the rates between arms. |
Up to 3 years
|
|
Completeness of cytoreduction
Lasso di tempo: Up to 3 years
|
Will be estimated. |
Up to 3 years
|
|
Conversion rate to surgical resection among those not deemed to be surgical candidates
Lasso di tempo: Up to 3 years
|
Will estimate the conversion rate to surgical resection among those not deemed to be surgical candidates prior to treatment and provide the 95% confidence interval as well. |
Up to 3 years
|
|
Progression-free survival (PFS)
Lasso di tempo: From study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on Response Evaluation Criteria in Solid Tumors 1.1 criteria, assessed up to 3 years
|
Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From study entry to the first of either disease progression or death from any cause, where disease progression will be determined based on Response Evaluation Criteria in Solid Tumors 1.1 criteria, assessed up to 3 years
|
|
Overall survival
Lasso di tempo: From study entry to death from any cause, assessed up to 3 years
|
Will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From study entry to death from any cause, assessed up to 3 years
|
|
Incidence of adverse events
Lasso di tempo: Up to 3 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 3 years
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Soluble mesothelin-related peptides (SMRP) and megakaryocyte potentiating factor (MPF)
Lasso di tempo: Up to 3 years
|
Will assess the association between two continuous biomarkers, MPF and SMRP, and best response to treatment prior to surgery, defined as response (complete response/partial response) versus no response (stable disease/progressive disease). Two separate logistic regression models will be used, one for each biomarker, with response status as the binary outcome and MPF or SMRP as the independent variable. The significance of the association will be evaluated using the Wald test from each model at a significance level of 0.05. Each biomarker will be assessed for skewness via visual inspection of histograms. If MPF or SMRP values appear markedly non-normal, will apply a logarithmic transformation to reduce skewness. To address zero values, a constant of 0.1 will be added to all observations before log transformation. Will explore the association of MPF and SMRP with the primary and secondary endpoints with and without accounting for treatment arm effects. |
Up to 3 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Aaron S Mansfield, Alliance for Clinical Trials in Oncology
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Aminoacidi, peptidi e proteine
- Proteine
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Terapia farmacologica
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Prodotti chimici inorganici
- Complessi di coordinamento
- Guanina
- Ipossantine
- Purinoni
- Purine
- Glutammati
- Aminoacidi, acido
- Aminoacidi
- Aminoacidi, dicarbossilico
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Ipertermia, indotta
- Isotipi di immunoglobulina
- Solfuri
- Anioni
- Ioni
- Elettroliti
- Idrogeno solforato
- Terapia di modalità combinata
- Chemioterapia, adiuvante
- Bevacizumab
- Pemetrexed
- Carboplatino
- Immunoglobulina G
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
- Disolfuri
- atezolizumab
- Procedure chirurgiche di citoriduzione
- Chemioterapia intraperitoneale ipertermica
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NCI-2021-08573
- U10CA180821 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2021-08573 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- A092001 (Altro identificatore: CTEP)
- A092001 (Altro identificatore: Alliance for Clinical Trials in Oncology)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .